Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients-Reference-Cited by-同舟云学术

Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients

Published:2020-02-21 Issue:2 Volume:15 Page:e0229469
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Djebbari Faouzi^ORCID,Sharpley Faye A.,McLain-Smith Susan,Vallance Grant^ORCID,Eyre Toby A.,Kothari Jaimal,Moore Sally,Ramasamy Karthik

Funder

Celgene

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference16 articles.

1. Cancer Research UK. Cancer statistics: Myeloma incidence statistics. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma/incidence. Accessed April 4, 2018

2. Management of multiple myeloma in the newly diagnosed patient;American Society of Hematology;Hematology,2017

3. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma;FIRST Trial Team;New England Journal of Medicine,2014

4. Continuous lenalidomide treatment for newly diagnosed multiple myeloma;MM-015 Investigators;New England Journal of Medicine,2012

5. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma;Alcyone Trial Investigators;New England Journal of Medicine,2018

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea;Advances in Therapy;2024-04-15

2. First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1;International Journal of Clinical Oncology;2023-08-07

3. Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation;Leukemia;2023-06-14

4. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227;Journal of Clinical Oncology;2023-02-20

5. The impact of COVID-19 on autologous stem cell transplantation in multiple myeloma: A single-centre, qualitative evaluation study;Supportive Care in Cancer;2022-06-03